REGRESSION OF LIVER FIBROSIS IN HCV CIRRHOTIC PATIENTS TREATED WITH INTERFERON-FREE THERAPIES
ANCA LEUŞTEAN 1,3, MIHAELA CRISTINA OLARIU 1,3*, NICOLETA MIHAI 1, CĂTĂLIN TILIŞCAN 2,3, VIOLETA MOLAGIC 1,3, IRINA DUPORT-DODOŢ 2,3, LAURENŢIU MIHĂIŢĂ STRATAN 1,3, ŞTEFAN SORIN ARAMĂ 2, VICTORIA ARAMĂ 1,3
1 Faculty of Medicine, “Carol Davila” University of Medicine and Pharmacy, 020021, Bucharest, Romania
2 Faculty of Dental Medicine, “Carol Davila” University of Medicine and Pharmacy, 020021, Bucharest, Romania
3 “Professor Doctor Matei Balş” National Institute for Infectious Diseases, 021105, Bucharest, Romania
4 Faculty of Pharmacy, “Carol Davila” University of Medicine and Pharmacy, 020021, Bucharest, Romania
Download Full Article PDF
The development of interferon-free treatments for hepatitis C virus (HCV) infection represents an important milestone in reducing the incidence of chronic HCV and mortality. The main objective of this study is to evaluate the regression of liver fibrosis in patients with HCV cirrhosis who registered SVR using the FibroTest and ActiTest scores. This study shows that there has been a reduction in liver fibrosis over seven years after SVR, as measured by the FibroTest score. This reduction seems to be more critical in the first six months post-EOT (mean FibroTest score of 0.84 (SD 0.07) vs. six months - mean 0.69 (SD 0.15), p < 0.001), directly correlating with the reduction in the necro-inflammatory activity (ActiTest – mean of 0.68 (SD 0.19) vs. six months 0.24 (SD 0.11), p < 0.001.). The reduction in FibroTest continues until three years post-EOT (mean 0.64) but does not have a statistically significant difference at the 7-year follow-up visit (mean 0.59, p = 0.733). The same dynamic is registered for ActiTest. Thus, we consider that monitoring patients with advanced liver disease (F3 and F4), especially in the first few years after achieving SVR, should also include the assessment of fibrosis through one of the non-invasive imaging or serological tests.
